Skip to main content

Event Details

Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection Corporate Conference Call
07/29/16 08:30 AM EDT
Webcast Presentation
Event Details
Title Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection Corporate Conference Call
Date and Time 07/29/16 08:30 AM EDT

Back to top